MedPath

Taspoglutide

Generic Name
Taspoglutide
Drug Type
Small Molecule
Chemical Formula
C152H232N40O45
CAS Number
275371-94-3
Unique Ingredient Identifier
2PHK27IP3B
Background

Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.

Clinical Trials
Related News

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Phase 3
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: placebo
First Posted Date
2008-09-01
Last Posted Date
2016-07-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
373
Registration Number
NCT00744926

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Phase 3
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: placebo
First Posted Date
2008-09-01
Last Posted Date
2016-08-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
326
Registration Number
NCT00744367

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Phase 3
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
First Posted Date
2008-07-17
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1189
Registration Number
NCT00717457

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Phase 2
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Placebo
First Posted Date
2007-04-17
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
133
Registration Number
NCT00460941

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Phase 2
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Placebo
First Posted Date
2007-01-18
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
306
Registration Number
NCT00423501
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy